Adam Levy

Chief Financial Officer, Mineralys Therapeutics, Inc.

Search every verified Adam Levy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Adam Levy, Chief Financial Officer of Mineralys Therapeutics, participated in the company’s second-quarter 2026 earnings call on August 11, 2026. During the call, he reported that the company ended the quarter with cash, cash equivalents, and investments of $661.4 million as of June 30, 2026, compared to $656.6 million as of December 31, 2025. He stated that the company believes its current cash position will be sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028. On the call, Levy also discussed ongoing payer dialogues for lorundrostat, describing them as "very positive" and noting that the level of rebates expected from the commercial side was consistent with company expectations, while Medicare access appeared to be via medical exception. He commented on the potential for the therapy to move earlier in lines of treatment, citing the overlap of hypertension, chronic kidney disease, and cardiovascular risk, and noted that the company sees aldosterone as a critical node in cardiometabolic disease. The call also confirmed that the company’s New Drug Application for lorundrostat remains under FDA review with a December 2026 PDUFA target date.